AstraZeneca has been drawn back to drug development innovation in China after accelerating its rate of licensing deals with biotechs in the country over the past few months. Meanwhile, the UK multinational has also been building a network ecosystem together with a Chinese investment bank to take a long-term view in the country, a senior R&D executive told Scrip in an interview.

The latest drug development news and highlights form the Pink Sheet’s US FDA Performance Tracker.

Having been used to navigating the Pacific with few obstacles, biotech companies taking advantage of Chinese resources and US innovation now face ballooning tensions between the two countries, which along with narrowing funding channels will increasingly force them to decide where to place their bets in the world’s largest economies.

Having been used to navigating across the Pacific with few obstacles, biotech companies taking advantage of Chinese resources and US innovation now face ballooning tensions between the two countries, which along with narrowing funding channels will increasingly force them to decide where to place their bets in the world’s largest economies.